Matching of 2012 Foot-and-Mouth disease virus SAT2 isolates and vaccine strain in Egypt

2015 ◽  
Vol 46 (1) ◽  
pp. 25-32
Viruses ◽  
2022 ◽  
Vol 14 (1) ◽  
pp. 97
Author(s):  
Nagendrakumar Balasubramanian Singanallur ◽  
Phaedra Lydia Eblé ◽  
Anna Barbara Ludi ◽  
Bob Statham ◽  
Abdelghani Bin-Tarif ◽  
...  

The recent emergence and circulation of the A/ASIA/G-VII (A/G-VII) lineage of foot-and-mouth disease virus (FMDV) in the Middle East has resulted in the development of homologous vaccines to ensure susceptible animals are sufficiently protected against clinical disease. However, a second serotype A lineage called A/ASIA/Iran-05 (A/IRN/05) continues to circulate in the region and it is therefore imperative to ensure vaccine strains used will protect against both lineages. In addition, for FMDV vaccine banks that usually hold a limited number of strains, it is necessary to include strains with a broad antigenic coverage. To assess the cross protective ability of an A/G-VII emergency vaccine (formulated at 43 (95% CI 8–230) PD50/dose as determined during homologous challenge), we performed a heterologous potency test according to the European Pharmacopoeia design using a field isolate from the A/IRN/05 lineage as the challenge virus. The estimated heterologous potency in this study was 2.0 (95% CI 0.4–6.0) PD50/dose, which is below the minimum potency recommended by the World Organisation for Animal Health (OIE). Furthermore, the cross-reactive antibody titres against the heterologous challenge virus were poor (≤log10 0.9), even in those cattle that had received the full dose of vaccine. The geometric mean r1-value was 0.2 (95% CI 0.03–0.8), similar to the potency ratio of 0.04 (95% CI 0.004–0.3). Vaccination decreased viraemia and virus excretion compared to the unvaccinated controls. Our results indicate that this A/G-VII vaccine does not provide sufficient protection against viruses belonging to the A/IRN/05 lineage and therefore the A/G-VII vaccine strain cannot replace the A/IRN/05 vaccine strain but could be considered an additional strain for use in vaccines and antigen banks.


2020 ◽  
Vol 182 ◽  
pp. 104920
Author(s):  
Gyeongmin Lee ◽  
Ji-Hyeon Hwang ◽  
Jong-Hyeon Park ◽  
Min Ja Lee ◽  
Byounghan Kim ◽  
...  

1978 ◽  
Vol 80 (3) ◽  
pp. 451-459 ◽  
Author(s):  
E. C. Anderson ◽  
W. J. Doughty ◽  
J. Anderson ◽  
D. Baber

SummaryFoot-and-mouth disease virus isolates of types O, A and SAT 2, from diseased animals in herds routinely vaccinated twice a year were compared antigenically with the vaccine strains in the complement-fixation, neutralization and radial immunodiffusion tests. It was found that strains which had readily infected vaccinated cattle had R values against the vaccine strain in the complement- fixation and radial immunodiffusion tests of 30 or less, while strains causing primary outbreaks with little spread had R values of 30–40. Threefold differences in humoral neutralizing antibody concentration between the field variant and the vaccine strain in sera from vaccinated animals were likely to be significant in terms of protection.


2019 ◽  
Vol 8 (37) ◽  
Author(s):  
M. Al Amin ◽  
M. Rahmat Ali ◽  
A. S. M. Rubayet Ul Alam ◽  
Mohammad Anwar Siddique ◽  
Huzzat Ullah ◽  
...  

The near-complete genome sequence of foot-and-mouth disease virus (FMDV) serotype A potential vaccine strain BAN/CH/Sa-304/2016 is reported here. Its genome revealed antigenic heterogeneity with the current Indian vaccine strain IND40/00, with four amino acid substitutions in antigenically critical sites of the VP1 protein.


2015 ◽  
Vol 3 (5) ◽  
Author(s):  
Muhammad Zubair Shabbir ◽  
Muhammad Munir

Sequencing and subsequent analysis of a vaccine strain of foot-and-mouth disease virus serotype O is reported here. Genomic heterogeneity in the protective epitopes (VP1 protein) of the reported strain, compared to characterized strains and available sequences from Pakistan, warrants further studies to determine vaccine-induced immunity and disease protection.


Author(s):  
B.P. Sreenivasa ◽  
J.K. Mohapatra ◽  
Veena Jumanal ◽  
V.V. Dhanesh ◽  
Saravanan Subramaniam ◽  
...  

Vaccine ◽  
2011 ◽  
Vol 29 (46) ◽  
pp. 8230-8240 ◽  
Author(s):  
Eduardo Maradei ◽  
Claudia Perez Beascoechea ◽  
Viviana Malirat ◽  
Gustavo Salgado ◽  
Cristina Seki ◽  
...  

Virus Genes ◽  
2007 ◽  
Vol 35 (3) ◽  
pp. 635-642 ◽  
Author(s):  
Junzheng Du ◽  
Huiyun Chang ◽  
Guozheng Cong ◽  
Junjun Shao ◽  
Tong Lin ◽  
...  

2010 ◽  
Vol 6 (12) ◽  
pp. e1001027 ◽  
Author(s):  
Richard Reeve ◽  
Belinda Blignaut ◽  
Jan J. Esterhuysen ◽  
Pamela Opperman ◽  
Louise Matthews ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document